AgeneBio

AgeneBio is a private, pre-revenue biotech founded in 2010 and headquartered in Indianapolis, Indiana. The company is advancing a novel therapeutic approach targeting neural overactivity to prevent Alzheimer's dementia, with its lead asset, AGB101, in a pivotal Phase 2b/3 trial for amnestic Mild Cognitive Impairment (MCI) due to Alzheimer's disease. Led by founder and CEO Dr. Michela Gallagher, a renowned neuroscientist from Johns Hopkins University, the company leverages deep scientific expertise and a management team with proven drug development experience. AgeneBio operates in a high-need, high-value market with no currently approved treatments for its lead indication.

Targets neural circuit overactivity, particularly in the hippocampus, using GABAergic modulation. Platform includes repurposed low-dose levetiracetam (AGB101) and a discovery program for novel GABA A α5 positive allosteric modulators.

AgeneBio competes in the high-stakes Alzheimer's prevention space, facing competition from large pharma and biotechs developing anti-amyloid (e.g., lecanemab), anti-tau, and other novel mechanism therapies. Its differentiation lies in targeting neural circuit overactivity rather than protein pathology, potentially offering a complementary or alternative approach.